How Lipohypertrophy Develops and Affects Blood Sugar

Lipohypertrophy is a buildup of fatty tissue just beneath the skin at insulin injection sites, forming soft, rubbery lumps that can range from barely noticeable to several centimeters across. It affects roughly two-thirds of people who inject insulin regularly, making it one of the most common complications of insulin therapy. The condition is far more than cosmetic: injecting into these lumps disrupts insulin absorption, destabilizes blood sugar, and quietly drives up the amount of insulin a person needs each day.

What Happens in the Tissue

Insulin has a direct fat-building effect on the tissue it contacts. When insulin is delivered to the same small patch of skin over and over, the fat cells in that area both enlarge and multiply. Histological studies of lipohypertrophic lesions confirm this pattern of enlarged and increased numbers of fat cells compared with normal surrounding tissue.¹ The result is a distinct mass of adipose tissue, often described as feeling like a rubber ball under the skin. Some lumps are obvious to the touch, while others are buried deep enough that only an ultrasound can spot them.

The lumps tend to grow slowly, which is part of the problem. People who inject insulin multiple times a day can develop lipohypertrophy over months or years without realizing it, because the change is gradual and the area does not usually hurt. By the time the lump is large enough to see or feel, it has often been disrupting insulin absorption for a long time.

The Risk Factors That Matter Most

A large meta-analysis pooling data from multiple studies ranked the risk factors by how strongly each one predicts lipohypertrophy. Incorrect injection site rotation came out far ahead as the strongest contributor, with roughly nine times the odds of developing lumps compared with people who rotate correctly. Reusing needles tripled the odds. Injecting insulin for more than five years and taking more than two daily injections each roughly doubled the risk.²

The dominance of site rotation over all other factors is striking. In one study of over 200 patients, among those who correctly rotated their injection sites, only 5% had lipohypertrophy. Among those who had the condition, 98% either did not rotate at all or rotated incorrectly.³ The message is unambiguous: rotating sites is the single most protective behavior.

Needle reuse compounds the problem. When a pen needle is used multiple times, the tip bends and deforms, which increases tissue trauma and contributes to induration of the fat layer beneath the skin.⁴ A study in children with type 1 diabetes found that greater frequency of needle reuse correlated with more local complications including redness, bleeding, and leakage at the injection site.⁵ Earlier research confirmed that the duration of insulin use and the frequency of changing both needles and injection sites all independently influence whether lipohypertrophy develops.⁶

Why People Keep Injecting in the Same Spot

If site rotation is so protective, why do the vast majority of people with lipohypertrophy fail to do it? The answer involves a feedback loop driven by reduced pain. As a lump develops, the nerve endings in that tissue become less sensitive. Injecting into lipohypertrophic tissue genuinely hurts less than injecting into normal skin, so people naturally gravitate back to the same area.⁷ This is the most commonly cited reason in the literature for why patients do not alternate sites: the familiar injection spot feels easier and less painful, and injecting elsewhere feels like a step backward in comfort.

The result is a self-reinforcing cycle. Less pain at the lump encourages repeated injection there, which makes the lump grow, which further reduces pain, which further concentrates injections. Breaking this cycle requires deliberate effort, and it often requires guidance from a healthcare provider who can map out a structured rotation pattern across the abdomen, thighs, or other injection zones.

How Lipohypertrophy Disrupts Blood Sugar

Injecting insulin into lipohypertrophic tissue is like pouring water into a sponge instead of onto a flat surface. The insulin gets trapped, absorbed unpredictably, and released in irregular surges rather than the smooth, predictable curve a person’s dosing schedule assumes. This unreliable absorption creates two downstream problems at once: blood sugar spikes when the insulin fails to absorb on time, and unexpected drops when a stored bolus suddenly releases.

A systematic meta-analysis quantified the damage. People with lipohypertrophy had HbA1c levels about half a percentage point higher than those without, needed roughly 8 extra units of insulin per day, and were about five times more likely to experience significant swings in blood sugar.⁸ Half a percentage point on HbA1c may sound modest, but over years that difference translates into meaningfully higher risk of complications. And the extra insulin is not doing more work; it is compensating for an absorption problem that proper injection technique could prevent.

Individual studies have shown similar patterns across different populations. A Chinese study found that people with lipohypertrophy took about 11 extra units of insulin per day and had HbA1c roughly half a percentage point higher than those without lumps.⁹ When researchers used continuous glucose monitoring to compare what happens in lipohypertrophic tissue versus normal tissue in the same patients, the affected tissue produced significantly larger blood sugar swings, higher post-meal spikes, and greater overall variability.¹⁰

The encouraging flip side: when patients stopped injecting into their lipohypertrophic areas, their total daily insulin doses dropped significantly without any worsening of blood sugar control.¹¹ The insulin they were already taking simply worked better once it was injected into healthy tissue. This is why clinicians who treat lipohypertrophy seriously typically reduce insulin doses at the same time they redirect injection sites, to avoid hypoglycemia from the sudden improvement in absorption.

Why It Often Goes Undiagnosed

Despite being present in most insulin-injecting patients, lipohypertrophy is frequently missed during clinical visits. Part of the problem is that physical examination, even by trained hands, catches only a fraction of existing lumps. A prospective study in China found that ultrasound detected about 41% more patients with lipohypertrophy and over 60% more individual lesions than physical examination alone.¹² Another study found that nearly three-quarters of participants had subclinical lesions, lumps that were invisible and impalpable but clearly present on ultrasound.¹³

The picture is not entirely one-sided. A systematic review of ultrasound studies found that results varied depending on the training of the clinician. In studies where the examiners were specifically trained to detect lipohypertrophy by palpation, the agreement between physical exam and ultrasound was much closer. One study even found that skilled palpation detected more lumps than ultrasound did.¹⁴ The practical takeaway is that the quality of the exam matters enormously. If your healthcare provider regularly inspects and feels your injection sites at each visit, they are far more likely to catch problems early. If injection sites are never examined, which is common in rushed clinical settings, lipohypertrophy can grow for years unnoticed.

For people who want to check themselves, a simple technique works: press your fingertips firmly across each injection area and compare the texture to nearby skin where you never inject. Lipohypertrophic tissue feels firmer and thicker, sometimes with distinct borders. If you find something suspicious, bring it to your provider’s attention and ask about ultrasound confirmation.

What Actually Reverses It

The primary treatment is not a medication or a procedure. It is education about injection technique, specifically about site rotation, needle use, and the importance of avoiding the lumps. This sounds underwhelming until you see the data on how well it works when done thoroughly.

A UK intervention study that taught patients proper rotation and kept them away from their lipohypertrophic areas found that lumps either disappeared completely or shrank by about half within the study period. Injections into lipohypertrophic sites dropped by more than 75%, and most patients who had not been rotating correctly at baseline were doing so by the end.¹⁵ A French randomized controlled trial tested intensive injection technique education with follow-up reinforcement against a single educational session. Both groups improved, but the intensive group improved faster and more completely, with about two-thirds achieving ideal or acceptable injection habits by six months.¹⁶

A study that compared a structured rotation teaching program to standard care found that by six months, the group receiving structured education reduced their rate of lipohypertrophy from 50% to 30%, while the control group’s rate actually increased slightly.¹⁷ Systematic rotation remains the cornerstone of both prevention and management.¹⁸

One important caution when switching away from lipohypertrophic sites: your effective insulin dose will increase because healthy tissue absorbs insulin more efficiently. If you keep the same dose and start injecting into normal skin, you are at real risk for hypoglycemia. Dose adjustments should happen under clinical guidance, with more frequent blood sugar monitoring during the transition period.

When Surgery Becomes an Option

For lumps that persist despite months of correct injection technique, or that are large enough to cause pain and cosmetic distress, liposuction is a viable option. The earliest published case reported that the procedure immediately resolved a severe case that had not responded to conservative management.¹⁹

A recent review of all published case reports found 18 patients treated with liposuction for insulin-induced lipohypertrophy. The primary reason for surgery was cosmetic in every case, though some patients also cited pain or difficulty injecting. The volume of tissue removed varied widely, from small amounts to nearly three liters per patient. All patients were satisfied with the results, and three reported improved blood sugar control afterward. The only complications were minor surface irregularities in two patients.²⁰ The evidence base remains small, consisting entirely of case reports and one case series, so liposuction stays firmly in the category of last resort after behavioral changes have been given a fair trial.

Continuous Glucose Monitors Placed Over Lipohypertrophy

People who wear continuous glucose monitors sometimes wonder whether placing a sensor over or near a lipohypertrophic area will throw off its readings. A study in type 1 diabetes compared sensor accuracy in lipohypertrophic tissue versus normal tissue and found a counterintuitive result: sensors placed in lumpy areas were at least as accurate as those in healthy skin, and in some glucose ranges, they were slightly more accurate.²¹ The researchers speculated that the altered tissue may provide a more stable sensor environment, though this is not fully understood. In practical terms, lipohypertrophy does not appear to be a reason to avoid placing a CGM sensor at a particular site, which is good news for people who have limited areas of unaffected tissue.

The distinction matters: CGM sensors measure interstitial glucose, not injected insulin. The problem with injecting insulin into lipohypertrophy is that the drug gets trapped and absorbs erratically. A CGM sensor, by contrast, is just reading the fluid around it, so the altered tissue structure does not create the same disruption. Insulin delivery and glucose sensing are affected by lipohypertrophy through entirely different mechanisms, and the tissue changes that wreck insulin absorption do not appear to wreck glucose measurement.

The Financial Side

The extra insulin that people with lipohypertrophy need each day adds up. In the Chinese study cited earlier, patients with lumps spent roughly 40% more per day on insulin than those without.²² But the cost of wasted insulin is only part of the picture. Unstable blood sugar leads to more emergency visits for severe hypoglycemia and more hospital admissions for sugar spikes that spiral out of control.

An Italian study tracked these broader costs and found dramatic savings when patients received structured injection education. In the group that received intensive teaching, costs associated with severe hypoglycemia dropped by over 80%, and costs tied to symptomatic hypoglycemia dropped by over 90%, within the study period. Meanwhile, costs in the control group barely budged.²³ The investment required for this teaching is modest: trained nurses or diabetes educators spending dedicated time on injection technique during routine clinic visits. Compared with the downstream costs of poorly controlled diabetes, it is hard to imagine a cheaper intervention.

Despite this, injection site inspection and technique education remain underemphasized in routine diabetes care across most healthcare systems. The condition is common enough that the majority of insulin users have it, well understood enough that prevention is straightforward, and costly enough when ignored that health systems have clear financial reasons to prioritize it. The gap between what is known about lipohypertrophy and what actually happens in most clinic visits remains one of the more frustrating disconnects in diabetes management.²⁴